MarkGKrisMD

PubMed

• Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
  Owen, D. H., Jamie E Chaft, Filiz Oezkan, Mark G Kris, Paul A Bunn, Ignacio I Wistuba, David J Kwiatkowski, Dwight H Owen, Yan Tang, Bruce E Johnson, Jay M Lee, Gerard...> ;Nature Medicine. 2024 Jan 1
• Deep learning of cell spatial organizations identifies clinically relevant insights in tissue images.
  Wang, S., Rong, R., Zhou, Q., Yang, D., Zhang, X., Zhan, X., Wilhelm, C., Zhang, S., Pickering, C., Xie, Y., Xiao, G., Bishop, J., Chi, Z., Kris, M., Minna, J.> ;Nature Communications. 2023 Dec 11
• 1 citations
  Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.
  Dacic, S., Travis, W., Giltnane, J., Kos, F., Abel, J., Hilz, S., Fujimoto, J., Sholl, L., Ritter, J., Khalil, F., Liu, Y., Taylor-Weiner, A., Resnick, M., Yu, H., Hir...> ;Journal of Thoracic Oncology. 2023 Dec 7
• Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.
  Monica F Chen, Guilherme Harada, Dazhi Liu, Ray DeMatteo, Christina Falcon, Clare Wilhelm, Mark G Kris, Alexander Drilon, Victoria Gutgarts> ;Journal of Thoracic Oncology. 2024 Jan 1
• 2 citations
  Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
  Arielle Elkrief, Biagio Riccuiti, Joao V Alessi, Teng Fei, Hannah L Kalvin, Jacklynn V Egger, Hira Rizvi, Rohit Thummalapalli, Guiseppe Lamberti, Andrew Plodkowski, Ma...> ;The Oncologist. 2023 Nov 2
• 8 citations
  Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.
  Jay M Lee, Ciaran J McNamee, Eric Toloza, Marcelo V Negrao, Jules Lin, Elaine Shum, Amy L Cummings, Mark G Kris, Boris Sepesi, Ilze Bara, Nino Kurtsikidze, Katja Schul...> ;Journal of Thoracic Oncology. 2023 Nov 1
• 3 citations
  Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
  Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, Daniel Muldoon, Hira Rizvi, Arielle Elkrief, Jia Luo, Joao V Alessi, Federica Pecci, Giuseppe Lamberti, Ale...> ;Clinical Cancer Research. 2023 Nov 1
• Deep Learning of Cell Spatial Organizations Identifies Clinically Relevant Insights in Tissue Images.
  Shidan Wang, Ruichen Rong, Donghan M Yang, Xinyi Zhang, Xiaowei Zhan, Justin Bishop, Clare J Wilhelm, Siyuan Zhang, Curtis R Pickering, Mark G Kris, John Minna, Yang X...> ;Research Square. 2023 Jul 4
• 1 citations
  Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.
  Arielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R Preeshagul, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe L...> ;Journal for Immunotherapy of Cancer. 2023 Jul 1
• 1 citations
  Response to Repotrectinib After Development ofResistance Mutations on First- and Second-Generation TRK Inhibitors.
  Monica F Chen, Soo-Ryum Yang, Jinru Shia, Jeffrey Girshman, Sippy Punn, Clare Wilhelm, Mark G Kris, Emiliano Cocco, Alexander Drilon, Nitya Raj> ;JCO Precision Oncology. 2023 May 1
• 2 citations
  Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.
  Mark G Kris, Tetsuya Mitsudomi, Solange Peters> ;Translational Lung Cancer Research. 2023 Apr 28
• Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.
  Arielle Elkrief, Alex Makhnin, Khadeja A Moses, Linda S Ahn, Isabel R Preeshagul, Afsheen N Iqbal, Sara A Hayes, Andrew J Plodkowski, Paul K Paik, Marc Ladanyi, Mark G...> ;Clinical Cancer Research. 2023 Apr 14
• 5 citations
  Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer.
  Shidan Wang, Ruichen Rong, Donghan M Yang, Junya Fujimoto, Justin A Bishop, Shirley Yan, Ling Cai, Carmen Behrens, Lynne D Berry, Clare Wilhelm, Dara Aisner, Lynette S...> ;The Journal of Clinical Investigation. 2023 Jan 17
• ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy.
  Emily S Lebow, Narek Shaverdian, Jordan E Eichholz, Leah B Kratochvil, Megan McCune, Yonina R Murciano-Goroff, Justin Jee, Juliana Eng, Jamie E Chaft, Mark G Kris, Eka...> ;Frontiers in Oncology. 2023 Jan 1
• 25 citations
  Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
  Noura J Choudhury, Antonio Marra, Jane S Y Sui, Jessica Flynn, Soo-Ryum Yang, Christina J Falcon, Pier Selenica, Adam J Schoenfeld, Natasha Rekhtman, Daniel Gomez, Mic...> ;Journal of Thoracic Oncology. 2023 Apr 1
• Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non-small cell lung cancer.
  Harry B Lengel, Junting Zheng, Kay See Tan, Corinne C Liu, Bernard J Park, Gaetano Rocco, Prasad S Adusumilli, Daniela Molena, Helena A Yu, Gregory J Riely, Manjit S B...> ;The Journal of Thoracic and Cardiovascular Surgery. 2023 May 1
• 39 citations
  Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
  Justin Jee, Emily S Lebow, Randy Yeh, Jeeban P Das, Azadeh Namakydoust, Paul K Paik, Jamie E Chaft, Gowtham Jayakumaran, A Rose Brannon, Ryma Benayed, Ahmet Zehir, Mar...> ;Nature Medicine. 2022 Nov 1
• 5 citations
  Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas.
  Paul K Paik, Jia Luo, Ni Ai, Rachel Kim, Linda Ahn, Anup Biswas, Courtney Coker, Wanchao Ma, Phillip Wong, Darren J Buonocore, W Victoria Lai, Jamie E Chaft, Swarnali ...> ;Nature Communications. 2022 Oct 15
• 7 citations
  Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoa...
  Valerie W Rusch, Alan Nicholas, G Alexander Patterson, Salama N Waqar, Eric M Toloza, Eric B Haura, Dan J Raz, Karen L Reckamp, Robert E Merritt, Dwight H Owen, David ...> ;The Journal of Thoracic and Cardiovascular Surgery. 2023 Mar 1
• 81 citations
  Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
  Jamie E Chaft, Filiz Oezkan, Mark G Kris, Paul A Bunn, Ignacio I Wistuba, David J Kwiatkowski, Dwight H Owen, Yan Tang, Bruce E Johnson, Jay M Lee, Gerard Lozanski, Ma...> ;Nature Medicine. 2022 Oct 1
• 33 citations
  Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.
  Jonathan T Yang, N Ari Wijetunga, Elena Pentsova, Suzanne Wolden, Robert J Young, Denise Correa, Zhigang Zhang, Junting Zheng, Alexa Steckler, Weronika Bucwinska, Ashl...> ;Journal of Clinical Oncology. 2022 Nov 20
• 9 citations
  Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer.
  Semanti Mukherjee, Chaitanya Bandlamudi, Matthew D Hellmann, Yelena Kemel, Esther Drill, Hira Rizvi, Kaitlyn Tkachuk, Aliya Khurram, Michael F Walsh, Marjorie G Zauder...> ;Cancer Epidemiology, Biomarkers & Prevention. 2022 Jul 1
• 16 citations
  Deciphering radiological stable disease to immune checkpoint inhibitors.
  J Luo, S Wu, H Rizvi, Q Zhang, J V Egger, J C Osorio, A J Schoenfeld, A J Plodkowski, M S Ginsberg, M K Callahan, C Maher, A N Shoushtari, M A Postow, M H Voss, R R Ko...> ;Annals of Oncology. 2022 Aug 1
• 14 citations
  Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer.
  Anup Kumar Biswas, Seoyoung Han, Yifan Tai, Wanchao Ma, Courtney Coker, S Aidan Quinn, Ahmad Rushdi Shakri, Timothy James Zhong, Hanna Scholze, Galina G Lagos, Angelik...> ;Cancer Discovery. 2022 Apr 1
• 27 citations
  Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
  Katherine Pisters, Mark G Kris, Laurie E Gaspar, Nofisat Ismaila> ;Journal of Clinical Oncology. 2022 Apr 1
• Join now to see all

Journal Articles

• PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung Cancers  
  G J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, D F Halpenny, N Rekhtman, R Chen, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin..., Annals of Oncology
• YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics  
  Emmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences

Lectures

• What, When, and How? Juggling Sequence and Agent Choices 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• 7th Annual New York Lung Cancer Symposium 
  Physicians' Education Resource, LLC, New York, New York - 11/10/2012
• 7th Annual New York Lung Cancer Symposium 
  Physicians' Education Resource, LLC, New York, New York - 11/10/2012
• Join now to see all